Literature DB >> 15502001

Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis.

M Ramos-Casals, P Brito-Zerón, N Nardi, G Claver, G Risco, F-D Parraga, S Fernandez, M Julià, J Font.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15502001     DOI： 10.1093/rheumatology/keh340

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  7 in total

Review 1.  Targeted therapy for systemic sclerosis: how close are we?

Authors:  Manuel Ramos-Casals; Vicent Fonollosa-Pla; Pilar Brito-Zerón; Antoni Sisó-Almirall
Journal:  Nat Rev Rheumatol       Date:  2010-04-13       Impact factor: 20.543

Review 2.  New lines in therapy of Raynaud's phenomenon.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

Review 3.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

4.  Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report.

Authors:  Joaquin De Haro; Aurora Florez; Jose Luis Fernandez; Francisco Acin
Journal:  BMJ Case Rep       Date:  2009-05-12

Review 5.  [Evidence-based therapy of Raynaud's syndrome].

Authors:  M Distler; J Distler; A Ciurea; D Kyburz; U Müller-Ladner; K Reich; O Distler
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

Review 6.  Advances in the treatment of Raynaud's phenomenon.

Authors:  Terri L Levien
Journal:  Vasc Health Risk Manag       Date:  2010-03-24

Review 7.  The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

Authors:  N S Kirkby; P W F Hadoke; A J Bagnall; D J Webb
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.